Clinical Trials Logo

Food Allergy Peanut clinical trials

View clinical trials related to Food Allergy Peanut.

Filter by:
  • None
  • Page 1

NCT ID: NCT06260956 Not yet recruiting - Clinical trials for Food Allergy in Infants

Expecting Mother's Study of Consumption or Avoidance of Peanut and Egg

ESCAPE
Start date: September 2024
Phase: N/A
Study type: Interventional

Peanut allergy is the most common cause of fatal and near-fatal food-allergic reactions and egg allergy is among the two most common causes of food-induced anaphylaxis. The proposed research will explore the development of sensitization to these food(s) in infants based on maternal consumption or avoidance during pregnancy and breastfeeding.

NCT ID: NCT06192914 Recruiting - Allergy Clinical Trials

EPAP, Interviewstudy

Start date: March 1, 2022
Phase:
Study type: Observational [Patient Registry]

The goal of this observational study is to learn about repetitive anaphylactic reactions in food allergic patients and to compare the frequency of repetitive reactions between different elicitors in food allergic patients. The main question it aims to answer are: • Is there an elicitor specific difference in the occurrence of anaphylactic reactions once the elicitor has been identified and the patient received counselling about its avoidance? Participants will answer questionnaires via a link they will receive via e-mail at baseline and 3, 6, 12 and 24 months after inclusion in the study.

NCT ID: NCT05695261 Recruiting - Food Allergy Clinical Trials

Evaluating the Safety and Efficacy of Oral Encapsulated Microbiota Transplantation Therapy in Peanut Allergic Patients

Start date: June 8, 2023
Phase: Phase 2
Study type: Interventional

This is a phase II randomized double-blind placebo-controlled trial that aims at evaluating the safety and tolerability of oral encapsulated fecal microbial transplantation therapy (MTT) in peanut allergic patients. In this research the investigators would like to learn more about ways to treat peanut allergies. The primary objective is to evaluate whether MTT with antibiotic pretreatment can increase the threshold of peanut reactivity during a double-blind placebo-controlled food challenge from <=100 mg peanut protein to 300 mg after 28 days of MTT /placebo therapy and 4 months post therapy initiation.

NCT ID: NCT05407012 Recruiting - Allergy;Food Clinical Trials

TRANS-FOODS: Preventing Peanut Allergy Through Improved Understanding of the Transcutaneous Sensitisation Route, Novel Food Processing and Skin Care Adaptations

TRANS-FOODS
Start date: April 5, 2024
Phase: N/A
Study type: Interventional

This project aims to study the immune responses to peanut allergen in those with a skin barrier defect with and without skin massage, specifically it aims to: 1. Establish if peanut allergen components can pass into human skin through regular massage using the peanut protein-containing extract. 2. Clarify whether this effect is amplified in those with an impaired skin barrier (AD and dry skin vs healthy controls). 3. Assess whether peanut protein components can be detected in interstitial skin fluid (ISF) using a suction device. 4. Test whether peanut protein components present in ISF are able to induce activation of basophils in blood of peanut allergic donors. 5. Assess whether the transcutaneous uptake of peanut protein can be reduced by the prior use of a barrier enhancing cream.

NCT ID: NCT05038904 Completed - Food Allergy Clinical Trials

Preventing Anaphylaxis With Acalabrutinib

Start date: December 16, 2021
Phase: Phase 2
Study type: Interventional

Food allergy is a potentially life-threatening condition, and its prevalence continues to increase despite public health efforts. There are currently no known therapies that can reliably prevent food-induced anaphylaxis. This is an open-label study designed to determine the ability acalabrutinib to prevent signs and symptoms of anaphylaxis during an oral food challenge in food-allergic adults.

NCT ID: NCT04604431 Enrolling by invitation - Clinical trials for Food Allergy in Infants

Intervention to Reduce Early (Peanut) Allergy in Children

iREACH
Start date: November 4, 2020
Phase: N/A
Study type: Interventional

iREACH is a five-year NIH funded study aimed at assessing and improving pediatric clinician adherence to the 2017 NIAID Prevention of Peanut Allergy (PPA) Guidelines. iREACH has been developed as an electronic health record (EHR) integrated Clinical Decision Support (CDS) tool together with educational modules on the PPA guidelines to assist clinicians in implementing the 2017 NIAID PPA Guidelines. A practice-based, two-arm, cluster-randomized clinical trial will evaluate the effectiveness of iREACH in increasing pediatric clinician adherence to the PPA Guidelines and explore the end-goal of reducing peanut allergy incidence by age 2.5 years in the intervention vs control group. This study has the potential to: 1) provide evidence regarding the effectiveness of iREACH in promoting clinical processes and outcomes related to the PPA Guidelines, 2) provide important insight about practice-based implementation of PPA Guidelines by pediatric clinicians, allergists and caregivers, and 3) facilitate rapid, widespread implementation of PPA Guidelines and reduce peanut allergy incidence across the US.

NCT ID: NCT04200989 Withdrawn - Food Allergy Peanut Clinical Trials

Novel Treatment for Patients With Peanut Allergy: Intralymphatic Immunotherapy

Start date: March 1, 2021
Phase: Phase 1/Phase 2
Study type: Interventional

Use of three intralymphatic injections of peanut allergen one month apart to induce tolerance to peanut in peanut allergic people.